Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CUE
CUE logo

CUE Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cue Biopharma Inc (CUE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
28.460
1 Day change
6.47%
52 Week Range
41.420
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Cue Biopharma Inc (CUE) is not a strong buy at the moment for a beginner investor with a long-term focus. The lack of significant trading trends, absence of positive news or catalysts, and neutral technical indicators suggest that the stock does not present a compelling entry point currently. With no Intellectia Proprietary Trading Signals active and no recent financial or valuation data available, it is advisable to hold off on investing in CUE for now.

Technical Analysis

The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), but the MACD is negatively contracting (-0.215), and RSI is neutral at 60.069. Key support and resistance levels are Pivot: 27.698, R1: 31.304, S1: 24.092, R2: 33.532, S2: 21.864. Overall, the technical indicators are mixed and do not strongly support a buy decision.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
2
Buy
8

Positive Catalysts

  • NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

  • No recent congress trading data, no news in the past week, and no significant trading trends from hedge funds or insiders. Additionally, the stock shows a 50% chance of a slight decline (-1.02%) over the next week.

Financial Performance

No financial data available for analysis. Latest quarter season not provided.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes provided. Wall Street sentiment is unclear.

Wall Street analysts forecast CUE stock price to rise
Analyst Rating
0
Wall Street analysts forecast CUE stock price to rise
Buy
Hold
Sell
0
Current: 26.730
sliders
Low
0
Averages
0
High
0
0
Current: 26.730
sliders
Low
0
Averages
0
High
0
Lucid Capital
Dev Prasad
Buy
initiated
$4
AI Analysis
2025-08-25
Reason
Lucid Capital
Dev Prasad
Price Target
$4
AI Analysis
2025-08-25
initiated
Buy
Reason
Lucid Capital analyst Dev Prasad initiated coverage of Cue Biopharma with a Buy rating and $4 price target. The company's lead asset CUE-401 is a novel bispecific for autoimmune disease, the analyst tells investors in a research note. The firm believes preclinical data show "strong mechanistic validation and broad efficacy" across autoimmune models.

People Also Watch